Alterity Therapeutics (ASX:ATH) Interest Received: A$1.52 Mil (TTM As of Dec. 2025)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
33 GF Score
Price A$0.71
View Full Analysis

What is Alterity Therapeutics Interest Received?

Alterity Therapeutics ASX:ATH +5.97% 33 Interest Received is A$1.52 Mil as of Dec. 2025. GuruFocus rates ASX:ATH with a GF Score™ of 33/100.

Alterity Therapeutics's Interest Received for the three months ended in Dec. 2025 was A$0.48 Mil.

Alterity Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.52 Mil.

Alterity Therapeutics Interest Received Related Terms

Alterity Therapeutics Interest Received Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Interest Received Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Received
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.00 0.02 0.27 0.45

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.30 0.34 0.48 0.41
ASX:ATH
33GF Score
Alterity Therapeutics Ltd ASX:ATH
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was A$1.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Received →
What does a Interest Received of A$1.52 Mil mean?
Alterity Therapeutics (ASX:ATH) has a Interest Received of A$1.52 Mil as of Dec. 2025. Interest Received represents interest received by the company in direct cash flow method. View historical data for Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Interest Received too high?
Alterity Therapeutics' current Interest Received is A$1.52 Mil. Overall, Alterity Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Interest Received compare to VRTX and REGN?
Alterity Therapeutics' Interest Received of A$1.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Received for a Biotechnology company?
A good Interest Received depends on the Biotechnology industry context. However, Interest Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Received mean?
A high Interest Received can signal that a stock is expensive relative to its fundamentals. Interest Received represents interest received by the company in direct cash flow method. View historical data for Alterity Therapeutics and its competitors. Alterity Therapeutics's current Interest Received is A$1.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Interest Received of A$1.52 Mil. The current Interest Received is A$1.52 Mil. Alterity Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Received calculated?
Interest Received is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Interest Received is A$1.52 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
33GF Score

Get the complete analysis for ASX:ATH

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.71
Price